Electroencephalography Devices Market

The global Electroencephalography Devices Market is valued at USD 1.43 Billion in 2024 and is projected to reach a value of USD 4.17 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 10.2% between 2025 and 2035.

The Electroencephalography Devices market is driven by the growing incidence of neurological disorders, the increasing need for non-invasive diagnostic methods, and advancements in EEG technology. The increasing elderly population and heightened awareness about the importance of early detection of neurological conditions are expected to drive market growth. For example, researchers at Western University developed a non-invasive method in March 2024 to improve the understanding of perfusion in hippocampal regions, which could aid in diagnosing neurological disorders like epilepsy, Alzheimer’s, and schizophrenia, thus supporting healthy aging.

According to the Alzheimer’s Association, in 2023, nearly 66% of those diagnosed with Alzheimer’s dementia in the U.S. were women. Of the 6.7 million people aged 65 and older with Alzheimer’s dementia, 4.1 million were women and 2.6 million were men, which represents 12% of women and 9% of men in this age group in the U.S. Furthermore, continued advancements in understanding brain functions and disorders are likely to fuel innovation in EEG technology, improving diagnostic capabilities and expanding its use in various neurological assessments and treatments. For instance, in July 2023, Yale Medicine reported that the U.S. FDA approved a new Alzheimer’s treatment, lecanemab, which showed a moderate reduction in cognitive and functional decline in individuals with early-stage Alzheimer’s disease.

Key Highlights

• In 2024, based on the Product, the 32-channel EEG category accounted for significant market share of 28.1%
• Based on the Type, the Standalone Devices category accounted for significant market share of 71.5% in 2024
• By Application, Disease Diagnosis dominated the market with market share of 30.5% in 2024
• In 2024, by End-Use, Hospitals dominated the market with significant market share of 66.5%
• North America dominated the market with 36.2% market share in 2024
• Asia Pacific region is anticipated to grow at the highest CAGR during the forecast period

Product Overview

​The Product segment is divided into 8-channel EEG, 21-channel EEG, 25-channel EEG, 32-channel EEG, 40-channel EEG, Multichannel EEG. The 32-channel EEG segment held the dominant share in 2024, accounting for significant market share of 28.1%.

The 32-channel EEG segment held the largest market share driven by the device's improved diagnostic accuracy and higher spatial resolution. The demand for EEG systems with increased channel capacity is rising as a result of the growing requirement for more thorough analysis of brain activity. For instance, in February 2024, Neurotechnology introduced enhanced BrainAccess EEG solutions featuring upgraded headwear, expanded software capabilities, and a new 32-channel system.

Type Overview

​The Type segment is divided into Standalone Devices, Portable Devices, Wearable Devices. The Standalone Devices segment held the dominant share in 2024, accounting for significant market share of 71.5%.

Standalone EEG devices function independently, without requiring additional equipment or connections, offering convenience and portability. Standalone EEG devices are ideal for usage in hospitals, clinics, and research facilities. As the need for remote patient monitoring POC diagnostics is rising, the demand for stand-alone systems are becoming more popular.

The portable EEG devices segment is expected to witness the fastest growth rate over the forecast period. These devices provide mobility and flexibility, allowing EEG recordings to be conducted outside traditional clinical environments. The rising demand for ambulatory EEG monitoring, particularly for diagnosing epilepsy and tracking sleep disorders, is expected to fuel the adoption of portable devices. For instance, in August 2023, researchers from the University of Houston tested and validated a wireless, cost-effective portable brain-computer interface that connects stroke patients’ brains to powered exoskeletons for rehabilitation.

Application Overview

​The Application segment is divided into Trauma & Surgery, Disease Diagnosis, Anesthesia Monitoring, Sleep Monitoring, Others. The Disease Diagnosis segment held the dominant share in 2024, accounting for significant market share of 30.5%.

EEG devices are essential for diagnosing neurological disorders such as epilepsy, Alzheimer’s, and Parkinson’s disease. For example, the University of Florida Health reported in February 2024 that the global Parkinson’s disease population has more than doubled from 3 million to over 6 million in the past 25 years, with projections to double again by 2040. The rising prevalence of these conditions, along with increasing awareness of the importance of early detection, is expected to drive demand for EEG devices in disease diagnosis. One such device, Prolira BV’s DeltaScan Brain State Monitor, offers clinicians a rapid, unbiased bedside assessment of acute brain failure, even detecting issues before symptoms appear, enabling timely treatment to restore cognitive health, as highlighted by Globetech Media in March 2023. Moreover, advancements in EEG technology, such as higher channel counts and improved signal processing algorithms, are enhancing the precision and reliability of diagnostic tests, fueling growth in this segment.

The trauma and surgery segment is projected to grow at the fastest CAGR during the forecast period. EEG devices are vital for monitoring brain activity during surgeries and managing Traumatic Brain Injuries (TBI). For instance, in January 2022, Lawrence + Memorial (L+M) Hospital implemented the Ceribell EEG Rapid Response monitor, which uses a headband, small data recorder, and an online platform to monitor neurological activity in critically ill patients. This device allows for early detection of silent seizures and enables immediate intervention. The increasing incidence of traumatic injuries and the rising need for real-time neurological monitoring during surgeries are expected to drive EEG adoption in this segment.

End-User Overview

The End-Use segment is divided into Hospitals, Diagnostics Centers, Others. In 2024, the Hospitals segment held largest share of 66.5% in the Electroencephalography Devices market.

Hospitals are increasingly adopting EEG devices for neurological diagnostics and monitoring, driven by the rising incidence of neurological disorders and the demand for advanced healthcare services. EEG devices are primarily used in hospitals to record and analyze brain rhythms and electrical activity for both clinical and research purposes, making hospitals the main end-users. For example, in July 2023, Nicklaus Children’s Hospital became one of the first institutions in the country to offer Transcranial Magnetic Stimulation (TMS) and a new High-density Electroencephalogram (HD EEG) system for pediatric care. Additionally, innovations like portable and wireless EEG devices are enhancing usability within hospitals, further contributing to market growth.

Regional Overview

In 2024, the North America captured 36.2% of the revenue share.

North America Electroencephalography Devices market is driven by the rising prevalence of neurological disorders and increased insurance coverage. Additionally, advanced healthcare infrastructure and strong distribution networks from leading vendors are expected to further fuel market growth. Favorable reimbursement policies in the U.S. have increased the adoption of EEG systems for diagnosing neurological disorders. Moreover, government support, including funding for research from institutions like the National Institute of Neurological Disorders and Stroke (NINDS), has bolstered the regional market.

The U.S. {Keyword}} market, valued at USD 372.3 Million in 2024 to USD 1105.7 Million in 2035, is anticipated to grow at a CAGR of 10.4% from 2025 to 2035. The U.S. Electroencephalography Devices market held a significant portion of the North American market in 2023, supported by the growing prevalence of neurological disorders like epilepsy, Alzheimer’s, and Parkinson’s diseases. Increased demand for advanced diagnostic technologies and favorable reimbursement policies are also key growth factors. For example, the CDC reported that in 2022, over 5.1 million people in the U.S. had a history of epilepsy, with 3.4 million currently affected. Additionally, the country's well-established healthcare system and robust distribution networks are expected to drive further market expansion.

In Europe, the Electroencephalography Devices market is poised for substantial growth due to an aging population and the rise in EEG device approvals by regulatory bodies. For instance, Brain Scientific's NeuroCap received CE mark approval in the EU in August 2022, demonstrating its ease of use with pre-gelled electrodes and quick EEG preparation times. The UK EEG devices market is also expected to grow, driven by the increasing number of neurological procedures. In 2022, the UK performed 73,729 neurology procedures, with further innovation in at-home EEG technology, like the collaboration between Cumulus Neuroscience and UK universities in 2023. France is experiencing growth due to an aging population, with 26% of the population over 60, and Germany’s EEG market is expanding due to mergers and acquisitions, such as Brainlab’s acquisition of Dr. Langer Medical GmbH.

The Asia-Pacific Electroencephalography Devices market is expected to grow the fastest during the forecast period, driven by the region’s large population, increased healthcare spending, and demand for advanced medical technologies. Japan, with the highest proportion of elderly people globally, is expected to see significant growth due to the aging population's higher susceptibility to neurological diseases. China’s EEG market is projected to grow rapidly due to increased urbanization and lifestyle changes that contribute to neurological conditions, including an anticipated rise in stroke incidence. Meanwhile, India’s market is expanding with growing efforts by established and emerging players, such as EEG research by the Indian Institute of Technology Madras in 2020.

In Latin America, the Electroencephalography Devices market is set for significant growth due to a rise in neurological disorders, greater healthcare awareness, and advancements in medical technology. Government initiatives and investments in healthcare infrastructure are expected to drive this expansion. Argentina, for instance, has established a regulatory framework for neurology devices overseen by the National Administration of Drugs, Food, and Medical Technology (ANMAT).

The Middle East and Africa region is also witnessing strong growth in the Electroencephalography Devices market, driven by the increasing prevalence of neurological disorders such as epilepsy, Alzheimer’s, and sleep disorders. Saudi Arabia, in particular, is advancing with projects like the tele-EEG services launched in February 2024 through the SEHA Virtual Hospital, which spans 24 hospitals and is supported by a network of EEG specialists. In Kuwait, the demand for EEG devices is rising due to increasing neurological treatments for conditions like epilepsy, Alzheimer’s, and Parkinson’s disease, as evidenced by the high volume of cases managed at Kuwait Hospital Sharjah.

Based on the provided market data, Vantage Market Research offers customizations in the reports to meet the specific needs of clients.

Key Trends

• Technological Advancements: Innovations such as portable and wireless EEG devices are enhancing diagnostic capabilities and patient comfort. The integration of artificial intelligence (AI) and machine learning algorithms is improving data analysis and interpretation, leading to more accurate and timely diagnoses
• Rising Prevalence of Neurological Disorders: An increase in conditions like epilepsy, Alzheimer's disease, and other neurological disorders is boosting the demand for EEG devices, as they are essential tools for diagnosis and monitoring
• Growing Adoption in Research and Clinical Settings: EEG devices are increasingly utilized in research to understand brain functions and in clinical settings for monitoring anesthesia depth, sleep disorders, and brain injuries, expanding their application scope
• Market Expansion in Emerging Economies: Developing regions are witnessing increased adoption of EEG devices due to improved healthcare infrastructure and greater awareness of neurological health, contributing to market growth
• Regulatory Approvals and Product Launches: Companies are focusing on obtaining regulatory clearances and launching innovative products to meet the growing demand, thereby enhancing their market presence

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Increasing Prevalence of Neurological Disorders

Conditions such as epilepsy, Alzheimer’s disease, Parkinson’s disease, and sleep disorders are becoming more prevalent due to factors like an aging population and lifestyle changes. For instance, as people age, the likelihood of developing neurological conditions increases, particularly Alzheimer’s disease and Parkinson’s. For instance, according to the Alzheimer's Association, around 12.7 million people aged 65 and older are expected to have Alzheimer's disease by 2050. The need for EEG devices has also increased since the value of early diagnosis for diseases like epilepsy and sleep problems is becoming more widely acknowledged.

High Cost of EEG Devices

High-end EEG devices, particularly those with more sophisticated features like high-channel configurations (32 or more channels) and integrated neuroimaging capabilities (such as combining EEG with functional MRI or MEG), can be prohibitively expensive. The expense of these systems is increased by the need for specialist equipment and the frequently difficult setup and maintenance procedures. The exorbitant cost of these sophisticated EEG equipment prevents their widespread use by healthcare providers, especially in underdeveloped nations. This cost factor may also limit the ability of smaller clinics and hospitals to invest in EEG technology, hindering market penetration in these areas.

Competitive Landscape

The Electroencephalography Devices market is marked by the presence of key players such as Medtronic, Nihon Kohden America, Inc., Natus Medical, Inc., Brain Products GmbH, Neurosoft, Compumedics Ltd., Electrical Geodesics, Inc., ANT Neuro, EBNeuro, Magstim EGI, Emotiv, Lifelines Neuro, Mitsar, Micromed, and Cadwell Laboratories Inc. As competitors seek to improve diagnostic precision and expand the therapeutic applications of EEG technology in neurology, mental health, and sleep disorder treatment, strategic alliances, mergers, and acquisitions, as well as research & development initiatives, are propelling market expansion.

The key players in the global Electroencephalography Devices market include - Medtronic, Nihon Kohden America, Inc., Natus Medical, Inc., Brain Products GmbH, Neurosoft, Compumedics Ltd., Electrical Geodesics, Inc., ANT Neuro, EBNeuro, Magstim EGI, Emotiv, Lifelines Neuro, Mitsar, Micromed, Cadwell Laboratories Inc. among others.

Recent Market Developments

Gate and Beacon Collaborate to Use EEG Biomarkers in Phase II Trial for Major Depressive Disorder

• In January 2024, Beacon and Gate began a collaboration to integrate EEG biomarkers into Gate's Phase II trial for Major Depressive Disorder (MDD). This trial, starting in mid-2024, will incorporate Beacon's Dreem 3S headband for exploratory EEG and sleep analysis in participants. The primary goal of the Phase II trial is to further the understanding and treatment options for MDD, focusing on Gate's investigational drug, zelquistine

Aditxt Acquires Brain Scientific’s EEG Monitoring Technologies, Expanding its Patent Portfolio

• in January 2024, U.S.-based biotechnology company Aditxt acquired EEG brain monitoring technologies and devices from Brain Scientific. The acquisition included 16 patents, featuring the disposable NeuroCap and the portable NeuroEEG device

Bath and Bristol Universities Receive USD 1.5 Million to Advance Fastball EEG Test for Early Dementia Detection

• In July 2023, a major funding of USD 1.5 million was awarded to the universities of Bath and Bristol to support the development of the Fastball EEG test. This user-friendly test is designed to aid in the early detection of dementia and Alzheimer's disease, benefiting both patients and their families

The global Electroencephalography Devices market can be categorized as Product, Type, Application , End-use and Region.